Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.
OPR, a statewide physician organization comprised of 140 oncologists representing 64 Michigan oncology practices, is working with oncology leaders from across Michigan, as well as P4 Healthcare, an oncology benefit management company, and BCBSM to develop the Michigan Oncology Clinical Treatment Pathways program. In this program, a statewide panel of oncology leaders have created up-to-date clinical guidelines for treating patients with lung, breast and colon cancer, as well as guidelines for supportive care. Supportive care products are used to prevent or treat the adverse side effects that arise as a result of the tumor itself or administration of cancer treatment. The guidelines will be shared with oncologists across Michigan as a way to provide cost-effective care and improve the quality of health care delivery, without compromising integrity or delivery of treatment.
"As a physician group comprised of and run by oncologists, our goal in this program was to address quality and efficiency of cancer care while ensuring that the integrity of the physician practice and the patient experience are not compromised," said Phil Stella, M.D., president and chief executive officer, OPR.
"Blue Cross Blue Shield of Michigan supports this program as part of our own efforts to assist the physician community while continually seeking to improve the care delivered to our members. We applaud the oncology community for their development of evidence-based pathways that can create high-quality and cost-effective care for patients," said Tom Simmer, M.D., chief medical officer, Blue Cross Blue Shield of Michigan.
P4 Healthcare, creators of the P4 Pathways program that serves as the foundation for this initiative, will provide proprietary technology, tools, expertise, educational programs and hands-on training for developing, implementing and continually monitoring and reporting on anything relating to the P4 Pathways program.
Practices implementing P4 Pathway programs have historically shown less variability in regimens, reduced misuse of chemotherapy, better managed toxicity, optimized use of biologics and more defined treatment milestones. The software tools are user friendly, have minimal impact on workload and require no hardware investment.
"P4 Pathways has grown tremendously and currently helps manage the treatment of 10 million lives across six states. The reason for this growth is that our proprietary technology provides real-time data and analysis coupled with evidence-based pathways and appropriate reimbursement, which has significantly improved patient outcomes with a substantial reduction in health care costs," said Jeffrey Scott, M.D., chief executive officer, P4 Pathways.
Machine learning models identify immunophenotypes in NSCLC for immunotherapy guidance